ReviewBiomedicines2026
Bridging Autoimmunity and Hyperinflammation: Shared Immunological Pathways Among Autoimmune/Inflammatory Syndrome Induced by Adjuvants, Systemic Lupus Erythematosus, and Macrophage Activation Syndrome.
Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) is characterized by immune dysregulation associated with exposure to exogenous substances with immunostimulatory properties, particularly in susceptible individuals. Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune disease characterized by loss of immune tolerance, autoantibody production, and immune complex deposition. Macrophage activation syndrome (MAS) is a life-threatening hyperinflammatory syndrome characterized by excessive activation of macrophages and T lymphocytes and may occur as a severe complication of SLE and other inflammatory conditions. This review explores the clinical and immunological overlap among ASIA, SLE, and MAS, with particular attention to the potential contribution of adjuvant-related exposures to immune activation in susceptible individuals. Shared and convergent immunological pathways, including activation of innate and adaptive immunity, loss of immune tolerance, macrophage activation, and dysregulation of cytokine networks involving IL-1β, IL-6, IL-17, IL-18, TNF-α, and interferon-γ, are discussed. Rather than representing an established causal or sequential pathway, the relationship among these conditions is considered within a conceptual framework based on overlapping immunological mechanisms. Clinically, overlapping manifestations among ASIA, SLE, and MAS may pose diagnostic challenges and contribute to underrecognition or delayed treatment. Careful assessment of potential triggering exposures, integration of clinical and laboratory findings, and prompt recognition of hyperinflammatory manifestations are important for appropriate clinical management. This review highlights the need for further mechanistic and prospective studies to determine the clinical relevance of the immunological overlap among ASIA, SLE, and MAS, validate potential biomarkers, and evaluate targeted therapeutic strategies directed at shared inflammatory pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.